Aptorum Group Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APM research report →
Companywww.aptorumgroup.com
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.
- CEO
- Chung Yuen Huen
- IPO
- 2018
- Employees
- 1
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $5.15M
- P/E
- -7.96
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- -4.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -3.24%
- ROIC
- -6.97%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,363,270 · 68.06%
- EPS
- $-0.19 · 75.64%
- Op Income
- $-1,817,528
- FCF YoY
- -54.14%
Performance & Tape
- 52W High
- $4.47
- 52W Low
- $0.65
- 50D MA
- $0.89
- 200D MA
- $1.26
- Beta
- 0.09
- Avg Volume
- 46.50K
Get TickerSpark's AI analysis on APM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our APM Coverage
We haven't published any research on APM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APM Report →